What should I avoid while taking Levomepromazine 100mg tablets?

Take with food. Food reduces irritation. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Levomepromazine 100mg tablets?

Levomepromazine 100mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Levomepromazine 100mg tablets?

Levomepromazine 100mg tablets is the generic name. It is available under brand names including: Levomepromazine 100mg tablets, Nozinan 100mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Levomepromazine 100mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

100mg

Oral

Antipsychotic

A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine.

Active ingredients:

Levomepromazine

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N05AA02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antipsychotic

Check interactions for Levomepromazine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Levomepromazine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Levomepromazine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Levomepromazine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

2 branded products available

2 productsShow details

2 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Levomepromazine on the MHRA register

Levomepromazine 100mg tablets

Morningside Healthcare Ltd

Nozinan 100mg tablets

Imported (New Zealand)

None

Imported

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Levomepromazine 6.25mg tablets

Tablet

6.25mg

Same therapeutic group

Levomepromazine hydrochloride 25mg/5ml oral solution sugar free

Oral solution

25mg/5ml

Same therapeutic group

Levomepromazine 3mg tablets

Tablet

3mg

Same therapeutic group

Levomepromazine 50mg tablets

Tablet

50mg

Same therapeutic group

Levomepromazine 1mg capsules

Capsule

1mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Clinical guidelines and formulary information

British National Formulary

Levomepromazine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

NG61

NICE guideline

Updated Jul 2019

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Levomepromazine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

27946311000001103

dm+d ID

27946311000001103

VTM (Virtual Therapeutic Moiety)

776520002

VMP (Virtual Medicinal Product)

27946311000001103

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N05AA02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

44 found

Half-life

20 hours

Mechanism

Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain.

Food interactions

1 warning

Human targets

19 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

50 to 60%

Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver.…

Half-life

20 hours

Approximately 20 hours.

Metabolism

Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Properties:

solid

Avg. mass: 328.47 Da

DrugBank indication

For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.

Also known as(74)

(-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine

(-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine

2-Methoxytrimeprazine

Levomepromazina

Levomepromazine

Lévomépromazine

Levomepromazinum

Methotrimeprazine

Dosage forms(23)

Tablet (Oral) — 100 mg

Tablet (Oral) — 10 MG

— 25 MG/ML

Solution (Oral) — 40 MG/ML

Solution (Oral) — 40 mg

Tablet, coated (Oral) — 100 mg

Tablet, coated (Oral) — 25 mg

Tablet (Oral) — 2 mg

Molecular properties(18)

Drug interactions(1803)

Known interactions with other medications. Always consult a healthcare professional.

Valsartan

Moderate

DB00177

Methotrimeprazine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Remikiren

Moderate

DB00212

Methotrimeprazine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Methotrimeprazine may decrease the antihypertensive activities of Torasemide.

Check this interaction

Guanadrel

Moderate

DB00226

Methotrimeprazine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Methotrimeprazine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Nitroprusside

Moderate

DB00325

Methotrimeprazine may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Methotrimeprazine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Fosinopril

Moderate

DB00492

Methotrimeprazine may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Methotrimeprazine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Benazepril

Moderate

DB00542

Methotrimeprazine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Bosentan

Moderate

DB00559

Methotrimeprazine may decrease the antihypertensive activities of Bosentan.

Check this interaction

Enalapril

Moderate

DB00584

Methotrimeprazine may decrease the antihypertensive activities of Enalapril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Methotrimeprazine may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Methotrimeprazine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Methotrimeprazine may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Eplerenone

Moderate

DB00700

Methotrimeprazine may decrease the antihypertensive activities of Eplerenone.

Check this interaction

Lisinopril

Moderate

DB00722

Methotrimeprazine may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Methotrimeprazine may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Cryptenamine

Moderate

DB00785

Methotrimeprazine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Methotrimeprazine may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Eprosartan

Moderate

DB00876

Methotrimeprazine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Quinapril

Moderate

DB00881

Methotrimeprazine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Methotrimeprazine may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Irbesartan

Moderate

DB01029

Methotrimeprazine may decrease the antihypertensive activities of Irbesartan.

Check this interaction

Deserpidine

Moderate

DB01089

Methotrimeprazine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Methotrimeprazine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Methotrimeprazine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

Methotrimeprazine may decrease the antihypertensive activities of Diazoxide.

Check this interaction

Guanethidine

Moderate

DB01170

Methotrimeprazine may decrease the antihypertensive activities of Guanethidine.

Check this interaction

Epoprostenol

Moderate

DB01240

Methotrimeprazine may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Hydralazine

Moderate

DB01275

Methotrimeprazine may decrease the antihypertensive activities of Hydralazine.

Check this interaction

Cilazapril

Moderate

DB01340

Methotrimeprazine may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Methotrimeprazine may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Methotrimeprazine may decrease the antihypertensive activities of Spirapril.

Check this interaction

Tienilic acid

Moderate

DB04831

Methotrimeprazine may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Sitaxentan

Moderate

DB06268

Methotrimeprazine may decrease the antihypertensive activities of Sitaxentan.

Check this interaction

Ambrisentan

Moderate

DB06403

Methotrimeprazine may decrease the antihypertensive activities of Ambrisentan.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Methotrimeprazine may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Pinacidil

Moderate

DB06762

Methotrimeprazine may decrease the antihypertensive activities of Pinacidil.

Check this interaction

Temocapril

Moderate

DB08836

Methotrimeprazine may decrease the antihypertensive activities of Temocapril.

Check this interaction

Riociguat

Moderate

DB08931

Methotrimeprazine may decrease the antihypertensive activities of Riociguat.

Check this interaction

Macitentan

Moderate

DB08932

Methotrimeprazine may decrease the antihypertensive activities of Macitentan.

Check this interaction

Aliskiren

Moderate

DB09026

Methotrimeprazine may decrease the antihypertensive activities of Aliskiren.

Check this interaction

Nicorandil

Moderate

DB09220

Methotrimeprazine may decrease the antihypertensive activities of Nicorandil.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Methotrimeprazine may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Enalaprilat

Moderate

DB09477

Methotrimeprazine may decrease the antihypertensive activities of Enalaprilat.

Check this interaction

Selexipag

Moderate

DB11362

Methotrimeprazine may decrease the antihypertensive activities of Selexipag.

Check this interaction

Angiotensin 1-7

Moderate

DB11720

Methotrimeprazine may decrease the antihypertensive activities of Angiotensin 1-7.

Check this interaction

Imidapril

Moderate

DB11783

Methotrimeprazine may decrease the antihypertensive activities of Imidapril.

Check this interaction

BQ-123

Moderate

DB12054

Methotrimeprazine may decrease the antihypertensive activities of BQ-123.

Check this interaction

Showing 50 of 1803 interactions

Food & lifestyle interactions

Take With Food

Take with food. Food reduces irritation.

Toxicity & overdose

Symptoms of overdose include convulsions, spastic movements, and coma.

How it works

Mechanism of action

Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.

Pharmacodynamics

Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.

Half-life

Approximately 20 hours.

Metabolism

Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.

Drug targets(19)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

D(1A) dopamine receptor

BE0000020

DRD1

antagonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

D(1B) dopamine receptor

BE0000145

DRD5

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

D(3) dopamine receptor

BE0000581

DRD3

antagonist

Specific functiondopamine neurotransmitter receptor activity, coupled via Gi/Go

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation

D(4) dopamine receptor

BE0000389

DRD4

antagonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Activated by dopamine, but also by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:9003072

Agonist binding triggers signaling via G proteins that inhibit adenylyl cyclase .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:7512953 PMID:7643093

Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity)

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2E1Cytochrome P450 2E1

inhibitor

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

ATC classification(1 code)

ATC N05AA02

Affected organisms(1)

Humans and other mammals

International brands(4)

Salt forms(2)

Methotrimeprazine hydrochloride(DBSALT002963)

Methotrimeprazine maleate(DBSALT002992)

Experimental properties(4)

Commercial products(24)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Methotrimeprazine

Matched from: Levomepromazine

DB01403

CAS number

60-99-1

UNII (FDA)

9G0LAW7ATQ

InChI Key (molecular fingerprint)

VRQVVMDWGGWHTJ-CQSZACIVSA-N

Synonym match

95% confidence

Additional database identifiers

Drugs Product Database (DPD)

8029

ChEBI

6838

PubChem Compound

72287

PubChem Substance

46507223

KEGG Compound

C07192

KEGG Drug

D00403

ChemSpider

65239

BindingDB

50418049

PharmGKB

PA164743234

Wikipedia

Levomepromazine

ChEMBL

CHEMBL1764

ZINC

ZINC000000020246

RxCUI

6852

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5182

GenAtlas

HRH1

GeneCards

HRH1

GenBank Gene Database

Z34897

GenBank Protein Database

510296

IUPHAR

262

Guide to Pharmacology

262

UniProtKB

P35367

UniProt Accession

HRH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1950

GenAtlas

CHRM1

GeneCards

CHRM1

GenBank Gene Database

X52068

GenBank Protein Database

34451

IUPHAR

Guide to Pharmacology

UniProtKB

P11229

UniProt Accession

ACM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1951

GenAtlas

CHRM2

GeneCards

CHRM2

GenBank Gene Database

M16404

GenBank Protein Database

177990

IUPHAR

Guide to Pharmacology

UniProtKB

P08172

UniProt Accession

ACM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1952

GenAtlas

CHRM3

GeneCards

CHRM3

GenBank Gene Database

X15266

GenBank Protein Database

32324

IUPHAR

Guide to Pharmacology

UniProtKB

P20309

UniProt Accession

ACM3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1953

GenAtlas

CHRM4

GeneCards

CHRM4

GenBank Gene Database

M16405

GenBank Protein Database

61970253

IUPHAR

Guide to Pharmacology

UniProtKB

P08173

UniProt Accession

ACM4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1954

GenAtlas

CHRM5

GeneCards

CHRM5

GenBank Gene Database

M80333

GenBank Protein Database

177988

IUPHAR

Guide to Pharmacology

UniProtKB

P08912

UniProt Accession

ACM5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

International reference pricing

5 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.07/tablet

To $3.60/ml

Apo-Methoprazine 2 mg Tablet

$0.07/tablet

Apo-Methoprazine 5 mg Tablet

$0.10/tablet

Apo-Methoprazine 25 mg Tablet

$0.27/tablet

Apo-Methoprazine 50 mg Tablet

$0.40/tablet

Nozinan 25 mg/ml

$3.60/ml

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Levomepromazine 100mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
21

Chemical identifiers

Methotrimeprazine

Additional database identifiers

International reference pricing

DrugBank citations

Levomepromazine 100mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science21

Chemical identifiers

Methotrimeprazine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
21